Update: UCB’s Bimzelx Approved By FDA, Offering 8-Week Dosing
UCB has received FDA approval for new single-injection device options of BIMZELX® (bimekizumab-bkzx) in 320 mg doses, expanding administration choices for patients with plaque psoriasis and psoriatic arthritis.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
